Company Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States.
The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME.
In addition, the company’s licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors.
Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis.
It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No.
4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012.
Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2010 |
| IPO Date | Nov 6, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 306 |
| CEO | Dennis Lanfear |
Contact Details
Address: 333 Twin Dolphin Drive, Suite 600 Redwood City, California 94065 United States | |
| Phone | 650 649 3530 |
| Website | coherus.com |
Stock Details
| Ticker Symbol | CHRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001512762 |
| CUSIP Number | 19249H103 |
| ISIN Number | US19249H1032 |
| Employer ID | 27-3615821 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dennis M. Lanfear | Chairman, President and Chief Executive Officer |
| Bryan J. McMichael | Former Interim Chief Financial Officer, Principal Financial and Acc. Off., SVice President-Acc. and Corporate Controller |
| Paul Reider | Chief Commercial Officer |
| Richard L. Hameister | Chief Technical Officer |
| Jodi Sievers | Vice President of Investor Relations and Corporate Communications |
| Andy Rittenberg | Executive Vice President of General Counsel |
| Scott Saywell | Executive Vice President of Corporate Development |
| Rebecca Sunshine | Chief Human Resources Officer |
| Michael Chen | Senior Vice President of Commercial Analytics and Trade |
| Dr. Theresa M. Lavallee Ph.D. | Chief Development Officer and Chairman of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 4, 2024 | 8-K | Current Report |
| Dec 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 3, 2024 | 8-K | Current Report |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 8-K | Current Report |